Recently, CStone, a Hong Kong-based innovative pharmaceutical company, and Kangsheng Global announced the signing of a strategic cooperation framework agreement. According to the agreement, the two parties have reached a number of cooperation intentions on precise diagnosis and treatment of hematological tumors, including: jointly carrying out relevant educational activities, enhancing the concept of precise detection and treatment in the field of hematological tumors, and leveraging their respective strengths to jointly explore and improve the treatment of acute myeloid leukemia (AML) patients in China The availability and standardization of IDH1 and other gene mutation detection, and the precise screening of patients who are suitable for the innovative targeted drug Tosuvo® (Avonib tablets) for hematological tumors, to promote Tosuvo® to accelerate the benefit of more Chinese patients. Tosuvo®, an oral targeted inhibitor of IDH1 mutant enzyme, has been approved by the China National Medical Products Administration for the treatment of adult relapsed or refractory (R/R) AML with IDH1 susceptibility mutations patient.

For this cooperation, Dr. Jiang Ningjun, CEO of CStone, said: "Precision diagnosis is the cornerstone of precise treatment, AML The accessibility and standardization of patient genetic testing still needs to be improved. Kangsheng Global has been deeply engaged in special inspection services in the field of hematology for a long time, and has many years of accumulation and precipitation in the field of hematology and tumors. We are very pleased to establish strategic cooperation with Kangsheng Global and look forward to its High-quality genetic testing services and extensive medical network coverage will work together to bring survival benefits to more Chinese IDH1-mutated AML patients.”

Professor Huang Shiang, founder and CEO of Kangsheng Global, said: "CStone Pharmaceuticals has a leading edge in the field of hematology and tumor, and is the first of its kind in the world. The drug Tosuvo® has changed the treatment pattern of IDH1-mutated AML. We are not looking forward to this cooperation. As the largest provider of special hematology testing services in China, we believe that with our broad market coverage and testing certified by international standards It will help improve the accessibility and standardization of blood tumor gene testing, and jointly protect the life and health of IDH1-mutated AML patients.”

Kangsheng Global is a large-scale high-end medical special inspection service inspection group in China, with offices in Beijing, Shanghai, Wuhan, Xinjiang, Chengdu, Tianjin has built 38,000 square meters of clinical testing, scientific research cooperation and application R&D laboratories with international advanced level, providing 3,000 medical supplies to more than 3,000 hospitals in 31 provinces and municipalities and more than 600 cities, especially more than 1,500 large-scale tertiary hospitals. A number of high-precision diagnostic tests for hematology, oncology and other specialties.

It is known that AML is the most common type of acute leukemia in adults, and about 6%-10% of AML patients carry IDH1 mutation. As the first potent and highly selective oral IDH1 inhibitor of its kind in the world, Topsuvo® has been unanimously recommended by four authoritative guidelines at home and abroad due to its clear clinical advantages, and has become the first choice for the treatment of IDH1-mutated AML. In June this year, Tuoshuwo® issued the first batch of prescriptions, which were officially supplied to more than 50 in-hospital and out-of-hospital DTP pharmacies in many provinces and cities across the country. CStone Pharmaceuticals is also actively accelerating the nationwide launch of Tosuwo®, which has been included in more than 5 cities in Huimin Insurance and commercial health insurance, such as Beijing Puhui Health Insurance Overseas Special Drug Catalog, Shanghai Huhuibao Overseas Special Drug Catalog, Hainan Lecheng Global Special Drug Insurance and Chengdu Huirong Insurance, etc. It is worth mentioning that since 2021, CStone has successively launched 4 new drugs for different therapeutic areas, and a total of 9 new drug applications (NDAs) have been approved, which is hailed as "cornerstone speed" in the industry.

In addition, Tosuvo® is actively exploring multiple new indications, including in adults with newly diagnosed IDH1-mutant AML First-line therapy for patients with IDH1-mutated locally advanced or metastatic cholangiocarcinoma and adult patients with relapsed/refractory myelodysplastic syndromes (MDS) with IDH1-susceptible mutations.